Evidence map›Paper›PMID 41153398›Full record

ArticleGenes2025

A New Variant in the NALCN Channel Is Responsible for Cerebellar Ataxia and Cognitive Impairment.

Rute Luísa Cabrita Pinto, Roberto Fancellu, Tiziana Benzi Markushi, Silvia Viaggi, Barbara Testa, Giuseppina Conteduca, Lane Fitzsimmons, Domenico Coviello, Angela Elvira Covone

Abstract readCase Reports
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rute Luísa Cabrita PintoLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0001-8192-5803
Roberto FancelluUnit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Tiziana Benzi MarkushiUnit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Silvia ViaggiLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0002-3732-9462
Barbara TestaLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0003-3516-2379
Giuseppina ConteducaLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0003-4301-3576
Lane FitzsimmonsRenaissance School of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY 11794, USA.
Domenico CovielloLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0001-8440-865X
Angela Elvira CovoneLaboratory of Human Genetics, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0002-7669-5270

Funding

Italian Ministry of Health, Ricerca Corrente #UAUT_2024_2043_0
6 · The paper itself

Abstract

BACKGROUND/

objectivesCLIFAHDD syndrome (OMIM # 616266) is a rare neurodevelopmental disorder caused by mutations in the NALCN gene. It is characterized by hypotonia, developmental delay, and congenital contractures of the limbs and face. We report a 33-year-old Italian woman with a mild form of CLIFAHDD who exhibited early-onset language difficulties and mild intellectual disability and later developed gait and balance impairments in adulthood. METHODS AND

resultsWhole Exome Sequencing (WES) identified a novel missense variant c.1514A>T; p.(Lys505Met) in the NALCN gene. The allele frequency of this variant is not detected (MAF = 0.0), the variant is classified as likely pathogenic according to ACMG criteria, and predicted to be probably damaging by PolyPhen-2. It affects a critical residue within the second pore-forming domain of the NALCN channel, potentially altering lipid interactions and channel regulation. Sanger sequencing and segregation analysis confirmed the variant to be heterozygous and de novo.

conclusionsThe patient's milder symptoms and later onset, compared to severe pediatric cases, suggest that the clinical spectrum of CLIFAHDD syndrome may be broader than previously recognized. These findings underscore the potential influence of mutation location on disease presentation and severity.

Indexed as

Cerebellar AtaxiaCognitive DysfunctionMembrane ProteinsAdultExome SequencingFemaleHumansIntellectual DisabilityIon ChannelsMutation, MissenseIon ChannelsMembrane ProteinsNALCN protein, humanCLIFAHDD syndromeNALCNneurodevelopmental disorderssodium channelsWhole Exome Sequencing

Identifiers

PMID41153398
PMCPMC12562970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.